Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: Implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Khanna, Dinesh ^a   Nagaraja, Vivek ^b   Tseng, Chi hong ^c   Abtin, Fereidoun ^c   Suh, Robert ^c   Kim, Grace ^c   Wells, Athol ^d   Furst, Daniel E ^c   Clements, Philip J ^c   Roth, Michael D ^c   Tashkin, Donald P ^c   Goldin, Jonathan ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cohort enrichment; Goh and Wells criteria; High resolution computed tomography; Interstitial lung disease; Randomized controlled trial; Scleroderma lung disease; Scleroderma Lung Study I (SLS I); Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PLETHYSMOGRAPHY; PREDICTION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; SCLERODERMA; SHORT FORM 36; SPIROMETRY; STAGING; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA, SYSTEMIC; X-RAY COMPUTED TOMOGRAPHY;

ADULT; CYCLOPHOSPHAMIDE; DIAGNOSIS, COMPUTER-ASSISTED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84951847053     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0872-2     Document Type: Article

References (39)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-4.
2. Murray LA, Rubinowitz A, Herzog EL. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol. 2012;24:656-62.
3. Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol. 2010;22:683-9.
4. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66:1967-78.
5. Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol. 2013;9:1077-90.
6. Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheumatol. 2014;26:607-14.
7. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-6.
8. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis. 1993;148:1076-82.
9. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47:738-42.
10. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63:2797-808.
11. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-54.
12. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63:3078-85.
13. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026-34.
14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
15. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-70.
16. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, et al. Systemic sclerosis-associated interstitial lung disease - proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol. 2010;28(2 Suppl 58):S55-62.
17. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977-83.
18. Kim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. 2010;28(5 Suppl 62):S26-35.
19. Kim HJ, Li G, Gjertson D, Elashoff R, Shah SK, Ochs R, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008;15:1004-16.
20. Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011;21:2455-65.
21. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum. 2007;56:1676-84.
22. Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, et al. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial-results from the Scleroderma Lung Study. Rheumatology (Oxford). 2009;48:1537-40.
23. Kim HJG, Brown MS, Goldin J, Abtin FG, Lynch DA, Strollo D, et al. Cyclophosphamide treatment versus placebo in Scleroderma Lung Study using total quantitative score of fibrosis, ground glass opacity, and honeycomb [abstract]. Am J Respir Crit Care Med. 2010;181(Meeting Abstracts):A2360.
24. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134:358-67.
25. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest. 2009;136:1333-40.
26. Dancey CP, Reidy J. Statistics without maths for psychology: using SPSS for Windows. 3rd ed. New York: Prentice Hall; 2004.
27. Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol. 2015;27:241-8.
28. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford). 2014;54:1944-53.
29. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med. 2014;35(2):213-21.
30. Steen VD, Lucas M, Fertig N, Medsger Jr TA. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007;34:2230-5.
31. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol. 2005;11:40-6.
32. Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206076.
33. Clements PJ, Tashkin D, Roth M, Khanna D, Furst DE, Tseng CH, et al. The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) [abstract 1075]. Arthritis Rheumatol. 2015;67(Suppl 10). http://acrabstracts.org/abstract/the-scleroderma-lung-study-ii-sls-ii-shows-that-both-oral-cyclophosphamide-cyc-and-mycophenolate-mofitil-mmf-are-efficacious-in-treating-progressive-interstitial-lung-disease-ild-in-patients-w/. Accessed December 12, 2015.
34. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med. 2006;354:2707-9.
35. Highland KB, Silver RM. Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the Scleroderma Lung Study. Curr Rheumatol Rep. 2005;7:135-41.
36. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189-91.
37. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.
38. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev. 2010;6:138-44.
39. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology. 2013;52:155-60.